Among the various aspects of the present disclosure is the provision of a hydrogel-based substrate comprising an aldehyde-containing component, such as N-ethanal acrylamide. The hydrogel component allows for functionalization of a hydrogel through conjugation of proteins (e.g., collagen) to the hydrogel in the absence of a post hoc crosslinking component.

Among the various aspects of the present disclosure is the provision of a hydrogel-based substrate comprising an aldehyde-containing component, such as N-ethanal acrylamide. The hydrogel component allows for functionalization of a hydrogel through conjugation of proteins (e.g., collagen) to the hydrogel in the absence of a post hoc crosslinking component.

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations. ##STR00001##

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations. ##STR00001##

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

The invention relates to a fatty amide, which is based on: a) a diamine selected from aromatic or cycloaliphatic or linear C.sub.2 to C.sub.10 aliphatic diamines, b) a C.sub.3 to C.sub.12 lactam or amino acid, c) optionally, a second primary diamine different from said diamine a), d) a hydroxylated fatty monoacid, e) optionally, a nonhydroxylated monoacid chosen from linear C.sub.6 to C.sub.12 aliphatic acids,
with a mole ratio b/(a+c) of 0.25 to 3/1. The invention also covers a process for the preparation of said amide and its use as organogelator or rheology additive in an organic solvent medium, in particular in coating, glue or adhesive, mastic, sealant or stripping agent compositions or molding or cosmetic compositions.